click on circles to display study description...

ACE, 2019 NCT02482753

tucidinostat plus exemestane (n=244) vs. exemestane (n=121)

randomized controlled trial

Studied treatment

tucidinostat plus exemestane
tucidinostat: PO 30mg twice a week for 4 consecutive weeks in a 4-week cycle / exemestane: PO 25mg/day

Control treatment

placebo plus exemestane
exemestane: PO 25mg/day

Patients

la/mBC - HR-positive - 2nd line (L2)

Method

double blind

at 22 centres in China

P3 / PFS at 2-sided at 0.05

Remark

tucidinostat added to exemestane increased significantly PFS comaper to exemestane monotherapy. OS data were still immature